Pharmeca.cz

Starting january 1, 2025, Pharmeca a.s. will provide an overview of issued decisions by the State Institute for Drug Control (SÚKL) and the Ministry of Health of the Czech Republic (MZ ČR) related to pricing and reimbursement on its website.

For marketing authorization holders, knowledge of SÚKL and MZ ČR decisions in the area of pricing and reimbursement is essential. The outcomes of individual proceedings shape decision-making practices that influence future decisions.

To address this need, Pharmeca a.s. now offers an interactive overview of decisions issued in the past five weeks.

Drug pricing and reimbursement are based on price referencing, where the foreign price in a foreign currency is converted into Czech koruna. For this purpose, it is essential to obtain the quarterly average exchange rate for the foreign exchange market, as published by the Czech National Bank.

Our new online overview provides:
✔ The required average exchange rate from the previous quarter
✔ The exchange rate development in the current quarter
✔ A monitoring focus on the 7 most commonly used European exchange rates in administrative proceedings

And all of this at a click!